l-Arginine Supplementation Protects Against Hepatic Ischemia–Reperfusion Lesions in Rabbits

Taha, Murched Omar; Simões, Manuel de Jesus; Haddad, Mansour; Capelato, R.C.; Budny, N.; Matsumoto, Akira; Soares, Paulo Cardoso; Santos, Wellington Martins dos; Armeato, G.D.; Araki, Chisato; Gomes, July Silveira; Magalhães, Kelly Grace; Tersariol, Ivarne L.S.; Monteiro, Hugo P.; Oliveira, Indhira Dias; Jurkiewicz, Aron; Caricati‐Neto, Afonso

doi:10.1016/j.transproceed.2009.02.050

Cited by 9 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our studies have shown that the administration of micromolar concentrations of L-arginine or sodium nitroprusside reduces the heart rate and contraction force of the isolated heart ventricle in rats submitted to prolonged tissue hypoxia [81,82,127]. Our studies also showed that administration of L-arginine produces protective actions against lesions by I/R injury in different organs, such as the liver and intestine [128,129]. These findings demonstrate that the L-arginine produces cardioprotective effects.…”

Section: Cardioprotective Strategies Against Myocardial Lesions Camentioning

confidence: 86%

Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection

Caricati‐Neto

Errante

Rodrigues

2019

IJMS

View full text Add to dashboard Cite

Ischemic heart diseases (IHD) are the leading cause of death worldwide. Although the principal form of treatment of IHD is myocardial reperfusion, the recovery of coronary blood flow after ischemia can cause severe and fatal cardiac dysfunctions, mainly due to the abrupt entry of oxygen and ionic deregulation in cardiac cells. The ability of these cells to protect themselves against injury including ischemia and reperfusion (I/R), has been termed “cardioprotection”. This protective response can be stimulated by pharmacological agents (adenosine, catecholamines and others) and non-pharmacological procedures (conditioning, hypoxia and others). Several intracellular signaling pathways mediated by chemical messengers (enzymes, protein kinases, transcription factors and others) and cytoplasmic organelles (mitochondria, sarcoplasmic reticulum, nucleus and sarcolemma) are involved in cardioprotective responses. Therefore, advancement in understanding the cellular and molecular mechanisms involved in the cardioprotective response can lead to the development of new pharmacological and non-pharmacological strategies for cardioprotection, thus contributing to increasing the efficacy of IHD treatment. In this work, we analyze the recent advances in pharmacological and non-pharmacological strategies of cardioprotection.

show abstract

Section: Cardioprotective Strategies Against Myocardial Lesions Camentioning

confidence: 86%

Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection

Caricati‐Neto

Errante

Rodrigues

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…In the current study, giving arginine significantly increased AST at all tested levels, however the sole increase in ALT was found in ewes given high arginine at late gestation. The increases of AST and ALT were observed in rabbits given L-arginine [37]. In spite of such increases of the activity of hepatic enzymes, it looks understandable that these tested doses of L-arginine are still within the physiological accepted levels.…”

Section: Discussionmentioning

confidence: 89%

L-Arginine Supplementation Alters Maternal Blood Biochemical Attributes and Milk Composition Relative to Neonatal Traits of <i>Najdi</i> Ewes

Zeitoun¹,

Al-Ghoneim²,

Al-Sobayil³

et al. 2019

OJAS

View full text Add to dashboard Cite

In a 2 × 3 factorial arrangement, 3 levels of L-arginine (0, 75 and 150 mg/kg BW per day) were tested at two stages of pregnancy (Early 60 days vs. Late 60 days) on the maternal blood metabolites and postnatal milk composition relative to the newborn traits of Najdi ewes.. Thirty adult pregnant Najdi ewes were randomly assigned into 6 treatments (n = 5). Control early (CE) ewes were orally administered 50 mL normal saline (0.9% NaCl) daily during the first 60 days of pregnancy; control late (CL) ewes were similar to CE except saline was given at the last 60 days of pregnancy; low dose of L-arginine at early pregnancy (LE); low dose of L-arginine at late pregnancy (LL); high dose of L-arginine at early (HE) and high dose of L-arginine at late pregnancy (HL). Blood and milk samples were collected on a weekly basis. Data of lambing and newborn traits were considered. There were non-significant differences in litter size due to L-arginine; however lamb birth and weaning weights increased by 35% in LE-ewes. Arginine did not change blood protein and albumin. Low arginine decreased lipid fractions, creatinine, urea, and milk fat; however, it increased AST, ALT, milk lactose and milk ash. Administration of L-arginine at 75 mg/Kg BW per day for 60 days at an early gestation in ewes improved the maternal body health and milk composition for the welfare of the neonates.

show abstract

“…Furthermore, it functions as a precursor for protein, creatine, and polyamine synthesis, besides aiding in ammonia neutralization and liver detoxification in patients with hepatic conditions ( Nanji et al, 2001 ). Animal models demonstrate the protective effects of arginine supplementation in liver injury syndromes, such as lipopolysaccharide-induced injury, hepatic ischemia–reperfusion injury, and acute cholestatic liver injury ( Muriel and González, 1998 ; Taha et al, 2009 ; Li et al, 2012 ). The regulation of ASS1 expression primarily hinges upon various stimuli like hormones, inflammatory mediators, cytokines, and lipopolysaccharides.…”

Section: Discussionmentioning

confidence: 99%

An integrated bioinformatics analysis to identify the shared biomarkers in patients with obstructive sleep apnea syndrome and nonalcoholic fatty liver disease

Zhang,

Liu,

et al. 2024

Front. Genet.

View full text Add to dashboard Cite

BackgroundObstructive sleep apnea (OSA) syndrome and nonalcoholic fatty liver disease (NAFLD) have been shown to have a close association in previous studies, but their pathogeneses are unclear. This study explores the molecular mechanisms associated with the pathogenesis of OSA and NAFLD and identifies key predictive genes.MethodsUsing the Gene Expression Omnibus (GEO) database, we obtained gene expression profiles GSE38792 for OSA and GSE89632 for NAFLD and related clinical characteristics. Mitochondrial unfolded protein response-related genes (UPRmtRGs) were acquired by collating and collecting UPRmtRGs from the GeneCards database and relevant literature from PubMed. The differentially expressed genes (DEGs) associated with OSA and NAFLD were identified using differential expression analysis. Gene Set Enrichment Analysis (GSEA) was conducted for signaling pathway enrichment analysis of related disease genes. Based on the STRING database, protein–protein interaction (PPI) analysis was performed on differentially co-expressed genes (Co-DEGs), and the Cytoscape software (version 3.9.1) was used to visualize the PPI network model. In addition, the GeneMANIA website was used to predict and construct the functional similar genes of the selected Co-DEGs. Key predictor genes were analyzed using the receiver operating characteristic (ROC) curve.ResultsThe intersection of differentially expressed genes shared between OSA and NAFLD-related gene expression profiles with UPRmtRGs yielded four Co-DEGs: ASS1, HDAC2, SIRT3, and VEGFA. GSEA obtained the relevant enrichment signaling pathways for OSA and NAFLD. PPI network results showed that all four Co-DEGs interacted (except for ASS1 and HDAC2). Ultimately, key predictor genes were selected in the ROC curve, including HDAC2 (OSA: AUC = 0.812; NAFLD: AUC = 0.729), SIRT3 (OSA: AUC = 0.775; NAFLD: AUC = 0.750), and VEGFA (OSA: AUC = 0.812; NAFLD: AUC = 0.861) (they have a high degree of accuracy in predicting whether a subject will develop two diseases).ConclusionIn this study, four co-expression differential genes for OSA and NAFLD were obtained, and they can predict the occurrence of both diseases. Transcriptional mechanisms involved in OSA and NAFLD interactions may be better understood by exploring these key genes. Simultaneously, this study provides potential diagnostic and therapeutic markers for patients with OSA and NAFLD.

show abstract

l-Arginine Supplementation Protects Against Hepatic Ischemia–Reperfusion Lesions in Rabbits

Cited by 9 publications

References 26 publications

Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection

Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection

L-Arginine Supplementation Alters Maternal Blood Biochemical Attributes and Milk Composition Relative to Neonatal Traits of <i>Najdi</i> Ewes

An integrated bioinformatics analysis to identify the shared biomarkers in patients with obstructive sleep apnea syndrome and nonalcoholic fatty liver disease

Contact Info

Product

Resources

About

l-Arginine Supplementation Protects Against Hepatic Ischemia–Reperfusion Lesions in Rabbits

Cited by 9 publications

References 26 publications

Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection

Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection

L-Arginine Supplementation Alters Maternal Blood Biochemical Attributes and Milk Composition Relative to Neonatal Traits of &lt;i&gt;Najdi&lt;/i&gt; Ewes

An integrated bioinformatics analysis to identify the shared biomarkers in patients with obstructive sleep apnea syndrome and nonalcoholic fatty liver disease

Contact Info

Product

Resources

About

L-Arginine Supplementation Alters Maternal Blood Biochemical Attributes and Milk Composition Relative to Neonatal Traits of <i>Najdi</i> Ewes